A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.

IF 1.5 4区 医学 Q3 DERMATOLOGY
Milaan Shah, Joshua Burshtein, Danny Zakria, Erin Boh, Michael Cameron, Brad Glick, Alexandra Golant, George Han, Sylvia Hsu, Benjamin Lockshin, Andrea Neimann, David Rosmarin, Mark Lebwohl
{"title":"A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.","authors":"Milaan Shah, Joshua Burshtein, Danny Zakria, Erin Boh, Michael Cameron, Brad Glick, Alexandra Golant, George Han, Sylvia Hsu, Benjamin Lockshin, Andrea Neimann, David Rosmarin, Mark Lebwohl","doi":"10.36849/JDD.8616","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic, inflammatory disease associated with numerous negative physical and psychosocial impacts. Deucravacitinib is a novel, selective TYK2 inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults. Deucravacitinib has established efficacy and safety through several clinical trials, but many clinicians are unfamiliar with its safety profile given the lack of formal guidelines. Thus, this expert consensus panel aims to provide clinical recommendations on the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the efficacy and safety of deucravacitinib. A panel of 10 dermatologists with expertise in managing psoriasis reviewed the relevant literature and crafted consensus statements regarding the efficacy, safety, and recommended laboratory monitoring for deucravacitinib. Using a modified Delphi process, each statement received supermajority approval and was assigned a strength of recommendation using the Strength of Recommendation Taxonomy (SORT) criteria.</p><p><strong>Results: </strong>The literature search resulted in 101 articles that met search criteria. After screening the articles for relevance to the discussion topic, 14 articles were selected and distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 6 consensus statements and recommendations, 5 of which were given a strength of \"A,\" 0 were given a strength of \"B,\" and 1 was given a strength of \"C.\"</p><p><strong>Conclusion: </strong>Deucravacitinib is an effective treatment for plaque psoriasis that is well-tolerated and has an excellent safety profile. The 6 consensus statements created by the panel provide expert recommendations regarding the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib. The expert panel also concludes that deucravacitinib has a superior safety profile to traditional JAK inhibitors. After reviewing the clinical trials, the panel did not find evidence of a causal role for deucravacitinib in inducing laboratory abnormalities and did not recommend baseline and ongoing laboratory monitoring for patients treated with deucravacitinib. J Drugs Dermatol. 2025;24(2):147-155. doi:10.36849/JDD.8616.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"147-155"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8616","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Psoriasis is a chronic, inflammatory disease associated with numerous negative physical and psychosocial impacts. Deucravacitinib is a novel, selective TYK2 inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults. Deucravacitinib has established efficacy and safety through several clinical trials, but many clinicians are unfamiliar with its safety profile given the lack of formal guidelines. Thus, this expert consensus panel aims to provide clinical recommendations on the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib.

Methods: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the efficacy and safety of deucravacitinib. A panel of 10 dermatologists with expertise in managing psoriasis reviewed the relevant literature and crafted consensus statements regarding the efficacy, safety, and recommended laboratory monitoring for deucravacitinib. Using a modified Delphi process, each statement received supermajority approval and was assigned a strength of recommendation using the Strength of Recommendation Taxonomy (SORT) criteria.

Results: The literature search resulted in 101 articles that met search criteria. After screening the articles for relevance to the discussion topic, 14 articles were selected and distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 6 consensus statements and recommendations, 5 of which were given a strength of "A," 0 were given a strength of "B," and 1 was given a strength of "C."

Conclusion: Deucravacitinib is an effective treatment for plaque psoriasis that is well-tolerated and has an excellent safety profile. The 6 consensus statements created by the panel provide expert recommendations regarding the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib. The expert panel also concludes that deucravacitinib has a superior safety profile to traditional JAK inhibitors. After reviewing the clinical trials, the panel did not find evidence of a causal role for deucravacitinib in inducing laboratory abnormalities and did not recommend baseline and ongoing laboratory monitoring for patients treated with deucravacitinib. J Drugs Dermatol. 2025;24(2):147-155. doi:10.36849/JDD.8616.

Deucravacitinib治疗斑块性银屑病的安全性和有效性综述:专家共识小组。
背景:牛皮癣是一种慢性炎症性疾病,与许多负面的身体和社会心理影响相关。Deucravacitinib是一种新型的选择性TYK2抑制剂,已被FDA批准用于治疗成人中至重度斑块性银屑病。Deucravacitinib已经通过几项临床试验确立了有效性和安全性,但由于缺乏正式的指南,许多临床医生对其安全性不熟悉。因此,这个专家共识小组旨在就deucravacitinib的有效性、安全性和适当的实验室监测提供临床建议。方法:综合检索PubMed、Scopus、谷歌Scholar等文献,检索有关deucravacitinib疗效和安全性的英文原创研究文章。一个由10名具有牛皮癣管理专业知识的皮肤科医生组成的小组审查了相关文献,并就deucravacitinib的有效性、安全性和推荐的实验室监测制定了共识声明。使用改进的德尔菲过程,每个语句获得绝对多数批准,并使用推荐强度分类法(SORT)标准分配推荐强度。结果:文献检索得到101篇符合检索标准的文献。在筛选了与讨论主题相关的文章后,选出了14篇文章分发给小组成员,供他们在圆桌讨论之前进行审查。专家组一致投票通过了6项共识声明和建议,其中5项被评为“a”,0项被评为“B”,1项被评为“C”。结论:Deucravacitinib是一种治疗斑块型银屑病的有效药物,具有良好的耐受性和良好的安全性。专家组制定的6项共识声明就deucravacitinib的疗效、安全性和适当的实验室监测提供了专家建议。专家小组还得出结论,与传统的JAK抑制剂相比,deucravacitinib具有更高的安全性。在回顾临床试验后,专家组没有发现deucravacitinib诱导实验室异常的因果作用的证据,也不建议对接受deucravacitinib治疗的患者进行基线和持续的实验室监测。皮肤医学杂志,2025;24(2):147-155。doi: 10.36849 / JDD.8616。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信